PDF(Sci-hub)
Abstract：
UNASSIGNED: Bioprosthetic valve deterioration remains a major limitation following aortic valve replacement. Favorable results have been reported with an autologous pericardium aortic valve neocuspidization.
UNASSIGNED: Seventy patients (31 women and 39 men) (mean age, 62 ± 12 years) with aortic stenosis (n = 52 [74%]) or aortic regurgitation (n = 18 [26%]) underwent the aortic valve neocuspidization procedure. Thirty-four patients (49%) had a tricuspid valve, 35 (50%) had a bicuspid valve, and 1 (1%) had a monocuspid valve. European System for Cardiac Operative Risk Evaluation and Society of Thoracic Surgeons scores were, respectively, 2.2% ± 2% and 2.0% ± 1.8%. Four patients (6%) had active endocarditis and 2 (3%) had endocarditis sequelae. One patient (1%) had fibroelastoma. A combined procedure was performed in 33 patients (46%).
UNASSIGNED: The follow-up period was 24 ± 12 months. One patient (1%) died in hospital and 1 patient (1%) underwent conventional valve replacement for significant aortic regurgitation. Postoperative peak and mean pressure gradients were respectively 14 ± 5 and 8 ± 3 mm Hg. Aortic valve area was 2.5 ± 0.6 cm2. During follow-up, no patients died. Reintervention occurred in 2 patients (3%). At last follow-up, peak pressure gradient was 13 ± 7 mm Hg, mean pressure gradient was 7 ± 4 mm Hg, and aortic valve area was 2.3 ± 0.7 cm2. There was 1 recurrence of moderate aortic stenosis (1%). All patients were in New York Heart Association functional class I (90%) or II (10%). Freedom from major valve-related events was 92.1%, (98.5% for death, 95.2% for reintervention, and 95.2% for endocarditis).
UNASSIGNED: In our experience, the midterm outcomes of the aortic valve neocuspidization procedure with autologous glutaraldehyde fixed pericardium were acceptable for survival, operative risk and valve-related complications, for our all-comer patient population with various aortic valve diseases.
UNASSIGNED: Seventy patients (31 women and 39 men) (mean age, 62 ± 12 years) with aortic stenosis (n = 52 [74%]) or aortic regurgitation (n = 18 [26%]) underwent the aortic valve neocuspidization procedure. Thirty-four patients (49%) had a tricuspid valve, 35 (50%) had a bicuspid valve, and 1 (1%) had a monocuspid valve. European System for Cardiac Operative Risk Evaluation and Society of Thoracic Surgeons scores were, respectively, 2.2% ± 2% and 2.0% ± 1.8%. Four patients (6%) had active endocarditis and 2 (3%) had endocarditis sequelae. One patient (1%) had fibroelastoma. A combined procedure was performed in 33 patients (46%).
UNASSIGNED: The follow-up period was 24 ± 12 months. One patient (1%) died in hospital and 1 patient (1%) underwent conventional valve replacement for significant aortic regurgitation. Postoperative peak and mean pressure gradients were respectively 14 ± 5 and 8 ± 3 mm Hg. Aortic valve area was 2.5 ± 0.6 cm2. During follow-up, no patients died. Reintervention occurred in 2 patients (3%). At last follow-up, peak pressure gradient was 13 ± 7 mm Hg, mean pressure gradient was 7 ± 4 mm Hg, and aortic valve area was 2.3 ± 0.7 cm2. There was 1 recurrence of moderate aortic stenosis (1%). All patients were in New York Heart Association functional class I (90%) or II (10%). Freedom from major valve-related events was 92.1%, (98.5% for death, 95.2% for reintervention, and 95.2% for endocarditis).
UNASSIGNED: In our experience, the midterm outcomes of the aortic valve neocuspidization procedure with autologous glutaraldehyde fixed pericardium were acceptable for survival, operative risk and valve-related complications, for our all-comer patient population with various aortic valve diseases.
摘要：
未经证实：主动脉瓣置换术后，生物瓣膜退化仍然是一个主要限制因素。已经报道了自体心包主动脉瓣新穿孔的良好结果。
未经评估：70名患者（31名女性和39名男性）（平均年龄，62±12年）的主动脉瓣狭窄（n=52[74％]）或主动脉瓣反流（n=18[26％]）接受了主动脉瓣新张法手术。34例患者（49%）有三尖瓣，35（50%）有二尖瓣，1（1％）有单叶瓣。欧洲心脏手术风险评估系统和胸外科医师协会评分为，分别,2.2%±2%和2.0%±1.8%。4例（6％）患有活动性心内膜炎，2例（3％）患有心内膜炎后遗症。1例患者（1%）患有纤维弹性瘤。33例患者（46％）进行了联合手术。
UNASSIGNED：随访24±12个月。1例患者（1％）在医院死亡，1例患者（1％）因严重的主动脉瓣反流而接受常规瓣膜置换术。术后峰值和平均压力梯度分别为14±5和8±3mmHg。主动脉瓣面积为2.5±0.6cm2。随访期间,没有病人死亡。2例患者（3%）发生再干预。在最后的随访中，峰值压力梯度为13±7mmHg，平均压力梯度为7±4mmHg，主动脉瓣面积为2.3±0.7cm2。1例中度主动脉瓣狭窄复发(1%)。所有患者均为纽约心脏协会功能等级I（90％）或II（10％）。无重大瓣膜相关事件的发生率为92.1%,（98.5％的死亡，95.2％用于再干预，心内膜炎为95.2％）。
未经评估：根据我们的经验，采用自体戊二醛固定心包的主动脉瓣新穿孔术的中期结局对于存活是可接受的,手术风险和瓣膜相关并发症，对于我们患有各种主动脉瓣疾病的所有患者。
未经评估：70名患者（31名女性和39名男性）（平均年龄，62±12年）的主动脉瓣狭窄（n=52[74％]）或主动脉瓣反流（n=18[26％]）接受了主动脉瓣新张法手术。34例患者（49%）有三尖瓣，35（50%）有二尖瓣，1（1％）有单叶瓣。欧洲心脏手术风险评估系统和胸外科医师协会评分为，分别,2.2%±2%和2.0%±1.8%。4例（6％）患有活动性心内膜炎，2例（3％）患有心内膜炎后遗症。1例患者（1%）患有纤维弹性瘤。33例患者（46％）进行了联合手术。
UNASSIGNED：随访24±12个月。1例患者（1％）在医院死亡，1例患者（1％）因严重的主动脉瓣反流而接受常规瓣膜置换术。术后峰值和平均压力梯度分别为14±5和8±3mmHg。主动脉瓣面积为2.5±0.6cm2。随访期间,没有病人死亡。2例患者（3%）发生再干预。在最后的随访中，峰值压力梯度为13±7mmHg，平均压力梯度为7±4mmHg，主动脉瓣面积为2.3±0.7cm2。1例中度主动脉瓣狭窄复发(1%)。所有患者均为纽约心脏协会功能等级I（90％）或II（10％）。无重大瓣膜相关事件的发生率为92.1%,（98.5％的死亡，95.2％用于再干预，心内膜炎为95.2％）。
未经评估：根据我们的经验，采用自体戊二醛固定心包的主动脉瓣新穿孔术的中期结局对于存活是可接受的,手术风险和瓣膜相关并发症，对于我们患有各种主动脉瓣疾病的所有患者。
